A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 478 participants.

Also called NCT03954834

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 478 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03954834
Other papers using this trial's data
  • Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Lancet (London, England), 2021-07-10 DOI, PubMed 34186022 PubMed links an erratum for this paper. Erratum: PMID 34274062

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, India, Japan, Mexico, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03954834. Randomized; double masking; primary purpose treatment. Start 2019-06-03 (actual); primary completion 2020-10-05 (actual). Results posted on 2021-10-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Acronym
SURPASS-1
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03954834
Content hash
dd7324ec1dcfc3478e3ac604687befac1fc698ae7ba4e61e7c15f0cfd9c4d024